Results 31 to 40 of about 477,291 (156)

The predictive value of PD‐L1 expression in patients with advanced hepatocellular carcinoma treated with PD‐1/PD‐L1 inhibitors: A systematic review and meta‐analysis

Cancer Medicine, 2023
Background and Aim Programmed death 1 (PD‐1) and programmed death ligand 1 (PD‐L1) inhibitors have transformed the treatment landscape of advanced hepatocellular carcinoma (HCC), but consistent responses are not observed in all patients, and prognostic ...
Yao Yang, Dongbo Chen, Bigeng Zhao, Liying Ren, Rui Huang, Bo Feng, Hongsong Chen   +6 more
doaj   +1 more source

High-Titer Hepatitis C Virus Production in a Scalable Single-Use High Cell Density Bioreactor

Vaccines, 2022
Hepatitis C virus (HCV) infections pose a major public health burden due to high chronicity rates and associated morbidity and mortality. A vaccine protecting against chronic infection is not available but would be important for global control of HCV ...
Anna Offersgaard, Carlos Rene Duarte Hernandez, Anne Finne Pihl, Nandini Prabhakar Venkatesan, Henrik Krarup, Xiangliang Lin, Udo Reichl, Jens Bukh, Yvonne Genzel, Judith Margarete Gottwein   +9 more
doaj   +1 more source

Risk factors for familial clustering of hepatitis C virus infection in a Chinese Han population: a cross-sectional study

BMC Public Health, 2018
Background Hepatitis C is a curable disease, but reinfection from household contact may occur in patients who have achieved sustained viral response (SVR).
Bi-fen Luo, Hui-ying Rao, Ying-hui Gao, Lai Wei   +3 more
doaj   +1 more source

SARS-CoV-2 Mpro inhibitor ensitrelvir: asymmetrical cross-resistance with nirmatrelvir and emerging resistance hotspots

Emerging Microbes and Infections
SARS-CoV-2 main protease (Mpro) inhibitors are the first-line COVID-19 treatment. Nirmatrelvir is used worldwide, while ensitrelvir, licensed in Japan and Singapore, has received FDA fast-track designation.
Yuyong Zhou, Karen A. Gammeltoft, Helena D. Tjørnelund-Sjursen, Line A. Ryberg, Anna Offersgaard, Anna Czarnota, Zhe Duan, Long V. Pham, Ulrik Fahnøe, Günther H.J. Peters, Santseharay Ramirez, Jens Bukh, Judith M. Gottwein   +12 more
doaj   +1 more source

MYL6B, a myosin light chain, promotes MDM2-mediated p53 degradation and drives HCC development

Journal of Experimental & Clinical Cancer Research, 2018
Background Identification of novel MDM2 or p53 binding proteins may reveal undefined oncogenes, tumor suppressors, signaling pathways and possible treatment targets.
Xingwang Xie, Xueyan Wang, Weijia Liao, Ran Fei, Nan Wu, Xu Cong, Qian Chen, Lai Wei, Yu Wang, Hongsong Chen   +9 more
doaj   +1 more source

Early predictive efficacy of core antigen on antiviral outcomes in genotype 1 hepatitis C virus infected patients

Brazilian Journal of Infectious Diseases, 2015
Response-guided therapy is of limited use in developing countries because hepatitis C virus RNA detection by sensitive molecular methods is time- and labor-consuming and expensive.
Bo Feng, Rui-Feng Yang, Hai-Ying Zhang, Bi-Fen Luo, Fan-Yun Kong, Hui-Ying Rao, Qian Jin, Xu Cong, Lai Wei   +8 more
doaj   +1 more source

Diagnosis and Monitoring of Hepatitis B Virus Infection Using the Cobas^® HBV Test for Use on the Cobas^® 4800 System

Microorganisms, 2021
(1) Background: Sensitive and accurate nucleic acid amplification technologies are now recommended for hepatitis B virus (HBV) DNA detection and quantification in clinical practice to diagnose and monitor hepatitis B infection.
Valérie Ortonne, Mélanie Wlassow, Magali Bouvier-Alias, Giovana Melica, Jean-Dominique Poveda, Syria Laperche, Jean-Michel Pawlotsky, Stephane Chevaliez   +7 more
doaj   +1 more source

Neutralisation resistance of SARS-CoV-2 spike-variants is primarily mediated by synergistic receptor binding domain substitutions

Emerging Microbes and Infections
The evolution of SARS-CoV-2 has led to the emergence of numerous variants of concern (VOCs), marked by changes in the viral spike glycoprotein, the primary target for neutralising antibody (nAb) responses. Emerging VOCs, particularly omicron sub-lineages,
Long V. Pham, Alexander P. Underwood, Alekxander Binderup, Ulrik Fahnøe, Carlota Fernandez-Antunez, Blanca Lopez-Mendez, Line Abildgaard Ryberg, Andrea Galli, Christina Sølund, Nina Weis, Santseharay Ramirez, Jens Bukh   +11 more
doaj   +1 more source

Peer-Delivered Hepatitis C Testing and Health Screening Provided in a Community Pharmacy Setting: Proof of Concept

Pharmacy
In order to reach and maintain hepatitis C virus (HCV) elimination goals, it is imperative to reach marginalized people who do not engage with traditional testing and treatment. Peer-led interventions are effective in engaging such individuals.
Neha Sankla, Ray Cottington, Chris Cowie, Paul Huggett, Leila Reid, Stuart Smith, Sorcha Daly, Danny Morris, James Spear, Amanda Marsden, David Richards, Rachel Halford, Scott Walter, Jenny Scott   +13 more
doaj   +1 more source

The significance of m6A RNA methylation regulators in predicting the prognosis and clinical course of HBV-related hepatocellular carcinoma

Molecular Medicine, 2020
Background Hepatocarcinogenesis is reportedly correlated with abnormal m6A modifications; however, it is unknown whether m6A RNA methylation regulators facilitate the occurrence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC).
Qiongxuan Fang, Hongsong Chen
doaj   +1 more source